OUR SCIENCE:

Our UNi-T Cell is an off-the-shelf solution that solves key challenges in adoptive cell therapy.

Persistent and potent cell therapies, with patient experience and access in mind.

Notch’s end-to-end capabilities in iPSC-T cell therapeutics development recognize and respond to the unique challenges posed by using living cells to treat complex disease. Our UNi-T Cell product, proprietary manufacturing processes, and internal product pipeline have been designed to improve on the clinical success of CAR-Ts while simultaneously tackling the associated commercial and economic challenges.

Our UNI-T Cell is programmed to drive safe, potent, and durable disease control.

In recent in vivo testing, our CAR UNi-T Cells eliminated tumors within the first week of study and maintained complete tumor remission. Our proof-of-concept studies demonstrate that UNi-T Cells target and kill target cells, safely expand in response to antigen cells and traffic to the site of the disease. We have also developed novel and potent approaches to protect UNi-T Cells from a patient’s immune system and eliminate the need for lymphodepleting chemotherapy.

Notch’s iPSC engineering platform generates uniformly engineered cell therapies. Drug potency is the same, no matter the cell batch and for every patient. Our CRISPR-based platform also mitigates safety and supply chain issues from viral vectors, while enabling sophisticated product designs to address multiple disease mechanisms.

Notch’s universal, allogeneic UNi-T chassis enables multiple product candidates and partnering opportunities.

Making cell therapy more drug-like. Delivering affordability and accessibility to the clinic.

To maximize their benefits to patients, cell therapies need to be available to people at the time of diagnosis. These products need to be shelf-stable, standardized, and affordable. Scalability drives cost, and Notch’s proprietary manufacturing process—which includes our regulatory-compliant, small-footprint bioreactor technology—enables unprecedented scale while delivering low variability in the products patients receive. Our UNi-T Cells may offer significantly reduced cost of manufacturing of CAR-T therapy, making it possible to enhance treatment outcomes for more patients than ever before.